PNS49 Are Multiple Brands Used to Charge Higher Prices for Orphan Drug Designations in the US?

Abstract

Authors

A. Rawal J. Hebert A. McVey

Full Text Cite This Article
Back to Volume 24, Supplemental S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×